About the symposiumOn Tuesday January 15th the 8th NEM Bleeding meeting will take place, which coincides with the 4th NEM multidisciplinary meeting. These one-day meetings are programmed by two separate committees covering different topics related to congenital bleeding disorders. The scientific bleeding symposium will touch upon diagnostic aspects of monitoring and managing Extended Half Life products and novel non-replacement therapies, immunological aspect of inhibitor formation in hemophilia, and upcoming novel treatment regimens directed against natural coagulation inhibitors in Hemophilia and Rare Bleeding Disorders. The multidisciplinary symposium will cover general aspects congenital bleeding disorder patients experience during their daily life.
Two plenary lectures will be given at the start and end of the meeting. The first lecture will be once more be given by Barend Heeren program manager at our Radboudumc Reshape Innovation center. He will discuss the outcome of our 30-days project related to hemophilia patients wellbeing. Prof dr. Thierry Vandendriessche (Brussel, Leuven, Gent) will give an overview about gene therapy with special emphasis to general gene therapy modalities also theoretically applicable in more rare bleeding disorders.
Tuesday January 15th, 9:30 to 18:00.
Concertgebouw De Vereeniging, Keizer Karelplein 2-D, 6511 NC Nijmegen.
Researchers, paramedics, medical professionals, and patients.
You can register by sending an email to email@example.com. Your registration will be accepted once we have received your payment.
Het inschrijvingsgeld bedraagt 50 euro (Scientific symposium), 35 euro (beroepsbeoefenaar, Multidisciplinair symposium) en 10 euro voor patiënten.
CostsThe registration fee consists of 50 euros (Scientific symposium), 35 euros (professional worker, Multidisciplinary symposium) and 10 euros for patients to account Radboud University Medical Centre, NL 90 ABNA 0231209983. Please mention project number: 005800/R0001753 HBC Radboudumc, 8th Nijmegen symposium and name of participant.
LocationDe Vereeniging, Keizer Karelplein 2-D, 6511 NC Nijmegen
9.30 - 10.10 Plenary session in English, Chairman: Waander van Heerde
9.30 - 09.40 Welcome and introduction, Waander van Heerde
9.40 - 10.10 Can gaming help improve risk management?, Barend Heeren
10.15 - 11.05 Lab diagnostics and Pharmacokinetics, Chairman: Tim Schuijt
10.15 - 10.40 Laboratory issues for measuring Extended half life molecules and novel
therapies in Haemophilia, Steve Kitchen
10.40 - 11.05 PK-guided dosing of factor VIII and IX: from population to individual, Tim Preijers
11.05 - 11.20 Coffee break
11.20 - 12.35 Novel treatment strategies directed against coagulation inhibitors in
hemophilia and RBD, Chairman: Saskia Schols
11.20 - 11.45 Re-engineering alpha-1-antitrypsin to inhibit activated protein C:
a universal haemostatic agent for haemophilia, Trevor Baglin
11.45 - 12.10 Restoring the balance in heamophilia by targeting TFPI, Tilman Hackeng
12.10 - 12.35 Potential of RNAi targeted against AntiThrombin, John Pasi
12.35 - 13.00 Small molecules directed against Antithrombin, Oliver Christophe
13.00 - 13.45 Lunch and demonstration of student-designed patient education materials
13.45 - 15.00 Inhibitors and immunological aspects of inhibitors, Chairman: Jan Voorberg
13.45 - 14.10 Emicizumab pro’s and cons: a biochemical perspective, Peter Lenting
14.10 - 14.35 Anti-drug antibodies in patients with hemophilia A, Jan Voorberg
14.35 - 15.00 The FLOW study – Unravelling inhibitor development in non-severe
Hemophilia A, Amal Abdi
15.00 - 15.15 Tea break
15.05 - 16.20 RBD and Personalized Medicine, Chairman: Erik Beckers
15.15 - 15.35 Rare Bleeding Disorders In the Netherlands update, Joline Saes
15.35 - 15.55 EHL-FVII in FVII deficiency, Britta Laros- van Gorkom
15.55 - 16.15 Personalized Medicine in bleeding disorders, Waander van Heerde
Plenary session in English, Chairman: Laurens Nieuwenhuizen
16.15 - 17.00 Gene therapy, Thierry Vandendriessche
17.00 - 17.10 Closing remarks, Waander van Heerde
17.10 - 18.00 Drinks and Bites